Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival

: The successful use of theranostic twins in neuroendocrine tumors (NET) was the pioneering approach to radionuclide therapy in other tumor types. 64Cu/18F PSMA for molecular imaging with PET-CT and peptide radioligand therapy (PRLT) with 177Lu labeled PSMA inhibitors are the next theranostic twins in nuclear medicine. 68Ga/ 64Cu/18F PSMA PET-CT detects metastatic prostate cancer with high diagnostic sensitivity and specificity and can be used to select patients for PRLT and evaluate therapy response. Radionuclide therapy with 177Lu-PSMA inhibitors has been shown to be effective in the treatment of metastatic CRPC.

Download Full-text

68Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy

Journal of Nuclear Medicine ◽

10.2967/jnumed.121.263006 ◽

2021 ◽

pp. jnumed.121.263006

Author(s):

Qaid Ahmed Shagera ◽

Carlos Artigas ◽

Ioannis Karfis ◽

Gabriela Critchi ◽

Nieves Martinez Chanza ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Metastatic Prostate Cancer ◽

Outcome Prediction ◽

Response Assessment ◽

Psma Pet ◽

Pet Ct

Download Full-text

Correlation of Iodine Quantification and FDG Uptake in Early Therapy Response Assessment of Non-small Cell Lung Cancer: Possible Benefit of Dual-energy CT Scan as an Integral Part of PET/CT Examination

Anticancer Research ◽

10.21873/anticanres.14332 ◽

2020 ◽

Vol 40 (6) ◽

pp. 3459-3468

Author(s):

JAN BAXA ◽

JAROSLAV LUDVIK ◽

MARTIN SEDLMAIR ◽

THOMAS FLOHR ◽

BERNHARD SCHMIDT ◽

...

Keyword(s):

Therapy Response ◽

Response Assessment ◽

Dual Energy ◽

Small Cell ◽

Dual Energy Ct ◽

Small Cell Lung ◽

Early Therapy ◽

Iodine Quantification ◽

Pet Ct ◽

Therapy Response Assessment

Download Full-text

Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT

Clinical Nuclear Medicine ◽

10.1097/rlu.0000000000001480 ◽

2017 ◽

Vol 42 (2) ◽

pp. 152-153 ◽

Cited By ~ 10

Author(s):

Wolfgang Roll ◽

Axel Bode ◽

Matthias Weckesser ◽

Martin Bögemann ◽

Kambiz Rahbar

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Radioligand Therapy ◽

Excellent Response ◽

Castration Resistant ◽

Psma Pet ◽

Pet Ct

Download Full-text

PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma

Seminars in Nuclear Medicine ◽

10.1053/j.semnuclmed.2017.09.003 ◽

2018 ◽

Vol 48 (1) ◽

pp. 28-36 ◽

Cited By ~ 10

Author(s):

Carsten Kobe ◽

Markus Dietlein ◽

Dirk Hellwig

Keyword(s):

B Cell ◽

Cell Lymphoma ◽

Therapy Response ◽

B Cell Lymphoma ◽

Response Assessment ◽

Large B Cell Lymphoma ◽

Pet Ct ◽

Therapy Response Assessment ◽

Post Therapy ◽

Large B Cell

Download Full-text

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [177Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome

Cancers ◽

10.3390/cancers13174270 ◽

2021 ◽

Vol 13 (17) ◽

pp. 4270

Author(s):

Philipp E. Hartrampf ◽

Constantin Lapa ◽

Sebastian E. Serfling ◽

Andreas K. Buck ◽

Anna Katharina Seitz ◽

...

Keyword(s):

Prostate Cancer ◽

Radioligand Therapy ◽

Psma Pet ◽

Number Of Patients ◽

Pet Ct ◽

Significant Difference ◽

Tracer Imaging ◽

Prognostic Implications ◽

Dual Tracer

Introduction: Positron emission tomography/computer tomography (PET/CT) targeting the prostate-specific membrane antigen (PSMA) is crucial for the assessment of adequate PSMA expression in patients with metastatic castration-resistant prostate cancer (mCRPC) prior to PSMA radioligand therapy (PSMA RLT). Moreover, initial dual tracer staging using combined PSMA and [18F]fluorodeoxyglucose (FDG) PET/CT provides relevant information, since discordant FDG-positive but PSMA-negative (FDG+/PSMA−) lesions constitute a negative prognostic marker of overall survival (OS) after PSMA RLT. However, little is known about the prognostic implications of dual tracer imaging for restaging at follow-up. The aim of this analysis was to investigate the prognostic implications of new FDG+/PSMA− lesions during or after PSMA RLT. Methods: This bicentric analysis included 32 patients with mCRPC who underwent both FDG and PSMA PET/CT imaging after two or four cycles of PSMA RLT. Patients with FDG+/PSMA− lesions prior to PSMA RLT were not considered. The presence of FDG+/PSMA− lesions was assessed with follow-up dual tracer imaging of patients after two or four cycles of PSMA RLT. Patients with at least one new FDG+/PSMA− lesion were compared to patients without any FDG+/PSMA− lesions at the respective time points. A log-rank analysis was used to assess the difference in OS between subgroups. Results: After two cycles of PSMA RLT, four of 32 patients (13%) had FDG+/PSMA− metastases. No significant difference in OS was observed (p = 0.807), as compared to patients without FDG+/PSMA− lesions. Follow-up dual tracer imaging after the 4th cycle of PSMA RLT was available in 18 patients. Of these, four patients presented with FDG+/PSMA− findings (n = 2 already after two cycles). After the fourth cycle of PSMA RLT, no significant difference in OS was observed between patients with and without FDG+/PSMA− lesions (p = 0.442). Conclusion: This study shows that FDG+/PSMA− lesions develop in a limited number of patients undergoing PSMA RLT. Further studies are needed to establish the clinical relevance of such lesions.

Download Full-text